Lucid Diagnostics Raises $15 Million in Series C Preferred Offering
PAVmed subsidiary Lucid Diagnostics raised $15 million in gross proceeds from accredited investors, selling 15,000 Series C Convertible Preferred shares at $1,000 each. The offering closed October 21, 2026.